Child HIV Exposure and CMV Seroprevalence in Botswana: No Associations With 24-Month Growth and Neurodevelopment.
Botswana
HIV-exposed uninfected
HIV-unexposed uninfected
anthropometrics
children
cytomegalovirus
neurodevelopment
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
17
04
2020
accepted:
18
08
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
Statut:
epublish
Résumé
We sought to identify predictors of child cytomegalovirus (CMV) infection overall and by maternal HIV status and to assess associations of child CMV status with growth and neurodevelopmental outcomes at 24 months of age in Botswana. Data and samples were used from the Botswana-based observational Tshipidi study (2010-2014), enrolling pregnant women living with and without HIV and following their infants through 2 years of age. Child plasma samples were tested at 18 months of age for anti-CMV immunoglobulin G (IgG). Associations were assessed between detectable anti-CMV IgG and growth (using the World Health Organization Child Growth Standards) and neurodevelopment (using the Bayley Scales of Infant and Toddler Development III and the Developmental Milestones Checklist) at 24 months of age. Of 317 children, 215 (68%) had detectable anti-CMV IgG at 18 months of age. Comparatively, 83% (n = 178) of HIV-unexposed uninfected (HUU) children had positive CMV serology vs 47% (n = 139) of HIV-exposed uninfected (HEU) children ( We observed high CMV seropositivity in 18-month-old children in Botswana, with higher seropositivity among breastfed (HUU) children. Positive CMV serostatus was not associated with 24-month child growth or neurodevelopmental outcomes, with the exception of smaller head circumference among HUU CMV-positive children.
Sections du résumé
BACKGROUND
BACKGROUND
We sought to identify predictors of child cytomegalovirus (CMV) infection overall and by maternal HIV status and to assess associations of child CMV status with growth and neurodevelopmental outcomes at 24 months of age in Botswana.
METHODS
METHODS
Data and samples were used from the Botswana-based observational Tshipidi study (2010-2014), enrolling pregnant women living with and without HIV and following their infants through 2 years of age. Child plasma samples were tested at 18 months of age for anti-CMV immunoglobulin G (IgG). Associations were assessed between detectable anti-CMV IgG and growth (using the World Health Organization Child Growth Standards) and neurodevelopment (using the Bayley Scales of Infant and Toddler Development III and the Developmental Milestones Checklist) at 24 months of age.
RESULTS
RESULTS
Of 317 children, 215 (68%) had detectable anti-CMV IgG at 18 months of age. Comparatively, 83% (n = 178) of HIV-unexposed uninfected (HUU) children had positive CMV serology vs 47% (n = 139) of HIV-exposed uninfected (HEU) children (
CONCLUSIONS
CONCLUSIONS
We observed high CMV seropositivity in 18-month-old children in Botswana, with higher seropositivity among breastfed (HUU) children. Positive CMV serostatus was not associated with 24-month child growth or neurodevelopmental outcomes, with the exception of smaller head circumference among HUU CMV-positive children.
Identifiants
pubmed: 33072807
doi: 10.1093/ofid/ofaa373
pii: ofaa373
pmc: PMC7539691
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa373Subventions
Organisme : NIAID NIH HHS
ID : K24 AI131928
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH087344
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009610
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI131924
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Clin Infect Dis. 2012 Feb 1;54(3):434-42
pubmed: 22247303
BMC Pediatr. 2017 Mar 16;17(1):80
pubmed: 28302082
JAMA. 2011 Feb 9;305(6):576-84
pubmed: 21304083
Clin Infect Dis. 2014 Mar;58(5):728-35
pubmed: 24265360
Clin Exp Immunol. 2014 Apr;176(1):11-22
pubmed: 24325737
Pediatrics. 2017 Oct;140(4):
pubmed: 28912368
Pediatrics. 2018 Feb;141(2):
pubmed: 29374109
Clin Microbiol Rev. 2013 Jan;26(1):86-102
pubmed: 23297260
AIDS. 2017 Aug 24;31(13):1809-1818
pubmed: 28609400
Clin Infect Dis. 2009 May 15;48(10):e93-5
pubmed: 19351268
Arch Dis Child Fetal Neonatal Ed. 2002 Sep;87(2):F75-7
pubmed: 12193509
Clin Infect Dis. 2014 May;58(10):1467-72
pubmed: 24567248
J Infect Dis. 2012 Dec 1;206(11):1695-705
pubmed: 23066160
Pediatrics. 2012 Nov;130(5):e1326-44
pubmed: 23118140
Acta Paediatr. 2014 Apr;103(4):447-54
pubmed: 24354938
AIDS Behav. 2014 Nov;18(11):2059-74
pubmed: 24729015
Front Immunol. 2016 May 06;7:164
pubmed: 27199989
Pediatr Infect Dis J. 2009 Jun;28(6):515-20
pubmed: 19483517
J Med Virol. 2016 Jun;88(6):1051-8
pubmed: 26519647
Virology. 2008 Dec 5;382(1):28-36
pubmed: 18929378
Clin Infect Dis. 2019 Oct 30;69(10):1789-1796
pubmed: 30615106
BMC Pediatr. 2015 Jun 06;15:66
pubmed: 26048411
Ital J Pediatr. 2011 Jan 19;37:6
pubmed: 21247481
J Pediatr. 2008 Jul;153(1):84-8
pubmed: 18571542
Pediatr Int. 2018 Jul;60(7):618-625
pubmed: 29663621
BMC Pregnancy Childbirth. 2014 Jan 08;14:7
pubmed: 24397463
Clin Infect Dis. 2012 Sep;55(6):877-84
pubmed: 22675157
J Pediatric Infect Dis Soc. 2016 Dec;5(suppl 1):S33-S40
pubmed: 27856674
AIDS. 2018 Aug 24;32(13):1781-1791
pubmed: 29794831
Acta Paediatr. 2010 Feb;99(2):291-7
pubmed: 20353499
AIDS. 2018 Jun 1;32(9):1173-1183
pubmed: 29547434
Pediatr Infect Dis J. 2010 Oct;29(10):915-8
pubmed: 20431424